

February 13, 2025

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Statement of Deviation and/or Variation in utilization of preferential issue proceeds for the quarter ended December 31, 2024

Ref: Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject read with the SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, issued by SEBI for Statement of Deviation or Variation for proceeds of public issue, right issue, preferential issue, Qualified Institution's Placement (QIP) etc., we Zota Health Care Limited enclosed herewith Statement of Deviation and/ or Variation (No Deviation and/ or Variation) on the captioned subject.

The above statement on Deviation and/ or Variation has been reviewed by the Audit committee of the Board in its meeting held on February 13, 2025.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya (Company Secretary & Compliance Officer)

Place: Surat Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street,

Sagrampura, Surat-395002 Ph: +91 261 2331601

Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352

Statement of Deviation / Variation in utilisatio		n of funds raised (Rs. in la							
Name of listed entity		ZOTA HEALTH CARE LIMITED							
Mode of Fund Raising		Preferential Issue							
Date of Raising Funds		(1) August 14, 2024							
		(2) December 04, 2024							
Amount Raised		 Rs. 4445.07 lakh comprising of Rs. 509/- per equity shares received on allotment of equity shares. This has been raised on August 14, 2024. Rs. 3365.55/- lakh upfront money comprising of Rs. 127.25/- (i.e 25% of Warrant Issue Price Rs. 509/-) per convertible Warrant received on subscription and allotment of convertible warrants. This has been raised on August 14, 2024. Rs. 623.87 lakh (being 75% of warrant Issue Price i.e Rs. 381.75/each) per fully convertible warrants received on conversion of 1,63,425 fully convertible warrants into equivalent number of equity 							
		shares. This has been raised on December 04, 2024.							
Report filed for Quarter ended		December 31, 2024							
Monitoring Agency		Applicable							
Monitoring Agency Name, if applica		CRISIL Ratings Limited							
Is there a Deviation / Variation in use of funds raised		No							
If yes, whether the same is pursuant to		Not Applicable							
change in terms of a contract or objects, which									
was approved by the shareholders									
If Yes, Date of shareholder Approval		Not Applicable							
Explanation for the Deviation / Variation		Not Applicable							
Comments of the Audit Committee after review		The Committee has noted that there is no deviation/ variation.							
Comments of the auditors, if any		No comments							
Objects for which funds have been	<u> </u>								
raised and where there has been a	deviation, in t	the following	table						
Original Object Modifie any	d Object, if	Original Allocation (Refer Note 1)	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if Any			

original object	any	Allocation (Refer Note 1)	allocation, if any	Utilised	Deviation/Variation for the quarter according to applicable object	if Any
Expansion of DAVAINDIA	Not Applicable	14325.83	Not	4920.62	Not Applicable	Not
Project			Applicable			Applicable
Working capital	Not Applicable	2686.09	Not	1918.87	Not Applicable	
requirement			Applicable			
General Corporate	Not Applicable	895.36	Not	95.00	Not Applicable	
Purpose			Applicable			
General Corporate	Not Applicable	895.36	Not	95.00	Not Applicable	

Note 1: Out of the issue proceeds of Rs 179.07 crore, the Company has received issue proceeds of Rs 84.34 crores till the quarter ended December 31, 2024. Further, the balance amount Rs 94.73 crore is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 (eighteen) months from the date of allotment of the Warrants i.e. February 13, 2026, as per the Notice to Shareholders dated July 13, 2024.

For **Zota Health Care Limited**

Ashvin Variya (Company Secretary & Compliance Officer)

Date: 13.02.2025